Labeling Update Alert: Librela® (bedinvetmab injection), NADA 141-562 Overview Librela® (bedinvetmab injection), the first monoclonal antibody approved in the U.S. to control osteoarthritis pain in dogs, received important label updates on February 18, 2025, under NADA 141-562. These changes reflect data gathered from real-world post-approval use since its U.S. launch in October 2023. [...]

Unapproved Pet Medications Are No Bargain—Here’s Why Your pet’s health and well-being are paramount, and when it comes to managing serious conditions like idiopathic epilepsy and seizures, the stakes couldn’t be higher. Recently, the FDA issued warnings to six online sellers of unapproved drugs that claim to treat or control seizures in dogs [...]